Pfizer has picked the TriNetX global health research network as its new “digital partner” for helping with clinical trials.
As a member of the network, Pfizer gains access to trial data from TriNetX’s network of healthcare organizations, which are designed to help across all trial processes, including retention.
TriNetX, which has CROs and biopharmas as clients, uses a cloud-based platform allowing researchers to deep dive into patient populations and perform “what-if” analyses in real-time.
“Users of the platform are presented with aggregate views, but each data point in the TriNetX network can be traced to healthcare organizations who have the ability to identify patients, allowing clinical researchers to develop virtual patient cohorts for potential recruitment into a clinical trial,” the company explained.
“Pfizer joined TriNetX to harness real world data for clinical trial optimization, with the goal of accelerating our ability to bring new therapies to market,” said Dr. Mohanish Anand, head of study optimization at Pfizer.
“Pfizer will use the real-time access to clinical, genomic and oncology data to design clinical trial protocols with greater efficiency. For example, we hope to reduce avoidable amendments by identifying and correcting overly restrictive inclusion and exclusion criteria early in the design process.”
This comes a few months after TriNetX Sanofi signed on to its tech—also to help streamline clinical trial design and accelerate drug development cycle times—and Cornell University’s Weill Cornell Medicine joined its healthcare organization network.
CEO of TriNetX Gadi Lachman added, “We are honored that Pfizer has selected us as digital partner to help in its strategic initiative to leverage real world data across its organization, from drug development to outcomes and healthcare research.”